JP2024541771A5 - - Google Patents

Info

Publication number
JP2024541771A5
JP2024541771A5 JP2024531113A JP2024531113A JP2024541771A5 JP 2024541771 A5 JP2024541771 A5 JP 2024541771A5 JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024541771 A5 JP2024541771 A5 JP 2024541771A5
Authority
JP
Japan
Prior art keywords
modified oligonucleotide
nucleic acid
item
nucleoside
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080448 external-priority patent/WO2023097291A1/en
Publication of JP2024541771A publication Critical patent/JP2024541771A/ja
Publication of JP2024541771A5 publication Critical patent/JP2024541771A5/ja
Pending legal-status Critical Current

Links

JP2024531113A 2021-11-24 2022-11-23 補体因子bを調節する組成物及びその使用方法 Pending JP2024541771A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163283177P 2021-11-24 2021-11-24
US63/283,177 2021-11-24
US202163287952P 2021-12-09 2021-12-09
US63/287,952 2021-12-09
US202263302976P 2022-01-25 2022-01-25
US63/302,976 2022-01-25
US202263339873P 2022-05-09 2022-05-09
US63/339,873 2022-05-09
PCT/US2022/080448 WO2023097291A1 (en) 2021-11-24 2022-11-23 Complement factor b-modulating compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024541771A JP2024541771A (ja) 2024-11-12
JP2024541771A5 true JP2024541771A5 (cg-RX-API-DMAC7.html) 2026-06-15

Family

ID=86540402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531113A Pending JP2024541771A (ja) 2021-11-24 2022-11-23 補体因子bを調節する組成物及びその使用方法

Country Status (14)

Country Link
US (1) US12595477B2 (cg-RX-API-DMAC7.html)
EP (1) EP4437104A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541771A (cg-RX-API-DMAC7.html)
KR (1) KR20240107360A (cg-RX-API-DMAC7.html)
CN (1) CN119256083A (cg-RX-API-DMAC7.html)
AU (1) AU2022396536B2 (cg-RX-API-DMAC7.html)
CA (1) CA3240273A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006751A2 (cg-RX-API-DMAC7.html)
IL (1) IL312928A (cg-RX-API-DMAC7.html)
MX (1) MX2024006368A (cg-RX-API-DMAC7.html)
PE (1) PE20241340A1 (cg-RX-API-DMAC7.html)
TW (1) TW202340463A (cg-RX-API-DMAC7.html)
WO (1) WO2023097291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4684015A2 (en) 2023-03-21 2026-01-28 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use
WO2025026228A1 (zh) * 2023-07-28 2025-02-06 苏州炫景生物科技有限公司 Cfb抑制剂组合物及其应用
WO2025151250A2 (en) * 2024-01-09 2025-07-17 Adarx Pharmaceuticals, Inc. Complement factor b-modulating compositions and methods of use thereof
WO2025256564A1 (en) * 2024-06-12 2025-12-18 Qilu Pharmaceutical Co., Ltd. iRNA COMPOSITION AND METHOD OF USING SAME

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2014107763A1 (en) 2013-01-08 2014-07-17 Benitec Biopharma Limited Age-related macular degeneration treatment
PL3043827T3 (pl) 2013-09-13 2020-03-31 Ionis Pharmaceuticals, Inc. Modulatory czynnika b dopełniacza
WO2015089368A2 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
CR20160554A (es) 2014-05-01 2017-03-07 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del factor b del complemento
CN119120476A (zh) 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
MX2022013606A (es) * 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
US20250136977A1 (en) 2021-09-02 2025-05-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
US20240401045A1 (en) * 2021-10-01 2024-12-05 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof
AR127477A1 (es) 2021-10-29 2024-01-31 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS

Similar Documents

Publication Publication Date Title
US5663312A (en) Oligonucleotide dimers with amide linkages replacing phosphodiester linkages
JP2023548584A5 (cg-RX-API-DMAC7.html)
JP2022519019A5 (cg-RX-API-DMAC7.html)
JP2024536146A5 (cg-RX-API-DMAC7.html)
JP2021074010A5 (cg-RX-API-DMAC7.html)
JP2025511183A5 (cg-RX-API-DMAC7.html)
JP2021515784A5 (cg-RX-API-DMAC7.html)
US20070179112A1 (en) Polymeric nucleoside prodrugs
JP2024079716A5 (cg-RX-API-DMAC7.html)
JP2021072862A5 (cg-RX-API-DMAC7.html)
JP2020511155A5 (cg-RX-API-DMAC7.html)
JP2021090458A5 (cg-RX-API-DMAC7.html)
JP2016513976A5 (cg-RX-API-DMAC7.html)
CA3094303A1 (en) Antisense oligonucleotide reduced in toxicity
JP2021522800A5 (cg-RX-API-DMAC7.html)
AR127325A1 (es) Métodos y composiciones para el tratamiento de la enfermedad renal poliquística
TW201919654A (zh) 用於抑制α-ENaC表現之RNAi試劑及使用方法
IL277970B1 (en) Oligomeric compounds comprising modified oligonucleotides and conjugate groups for use in treating end stage renal disease, chronic kidney disease, and coronary artery disease
JP2021522804A5 (cg-RX-API-DMAC7.html)
TW202304474A (zh) 用於抑制晚期糖化終產物之受體表現之RNAi藥劑、其組合物及使用方法
TW201920671A (zh) 單股寡核苷酸
JP2024534157A5 (cg-RX-API-DMAC7.html)
JP2023549563A5 (cg-RX-API-DMAC7.html)
JP2024511473A5 (cg-RX-API-DMAC7.html)
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法